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Abstract Glioblastoma multiforme (GBM) is the most
common primary brain tumor that is invariably lethal.
Novel treatments are desperately needed. In various can-
cers, heparin and its low molecular weight derivatives
(LMWHs), commonly used for the prevention and treat-
ment of thrombosis, have shown therapeutic potential.
Here we systematically review preclinical and clinical
studies of heparin and LMWHs as anti-tumor agents in
GBM. Even though the number of studies is limited, there
is suggestive evidence that heparin may have various
effects on GBM. These effects include the inhibition of
tumor growth and angiogenesis in vitro and in vivo, and the
blocking of uptake of extracellular vesicles. However,
heparin can also block the uptake of (potential) anti-tumor
agents. Clinical studies suggest a non-significant trend of
prolonged survival of LMWH treated GBM patients, with
some evidence of increased major bleedings. Heparin
mimetics lacking anticoagulant effect are therefore a
potential alternative to heparin/LMWH and are discussed
as well.
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Introduction
Glioblastoma multiforme (GBM) is the most common
primary brain tumor and is without exception lethal.
Despite (advances in) neurosurgery, radiation and
chemotherapy, median survival still does not extend
beyond 15 months, emphasizing a dire need for novel
treatments [1]. Most GBM patients are treated peri-opera-
tively with low molecular weight heparin (LMWH) for the
prevention of thrombotic complications. While LMWH is a
well-established drug for the prevention and treatment of
thrombosis, it has regained interest as a potential anti-
cancer agent. This interest in heparins as anti-cancer agents
was ignited by the sub-analysis [2] (n = 129) of two trials
published in 1992 [3, 4], indicating lower mortality rates
among cancer patients receiving LMWH as opposed to
heparin, a finding that was later disputed in a larger anal-
ysis (n = 672) that included brain tumor patients [5].
Interestingly though, a 2013 Cochrane meta-analysis found
a significant survival benefit for LWMH/heparin treated
patients after 24 months, but not after 12 months [6].
In vitro cancer studies indicate both heparin and LMWH
to inhibit angiogenesis, invasion, and metastasis of solid
tumors [7]. Moreover, the uptake of extracellular vesicles
(EVs), 50–1000 nm membrane vesicles, implicated in
GBM biology [8, 9], is blocked by heparin [10]. In animal
models for different, non-GBM tumors, heparin [11] and
LMWH [12] were shown to inhibit tumor growth and to
prolong survival. The effect of heparin-based therapies on
GBM tumors and thus its potential for GBM patients is
currently unknown. Here we systematically review
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literature on the effects of heparin/LMWH on GBM in
preclinical and clinical settings (Supplementary Table 1 for
search terms and Supplementary Fig. 1 for flow-chart).
Pharmacodynamic properties of heparin
Unfractionated heparin (UFH, here; heparin) is a highly sul-
fated glycosaminoglycan (GAG), closely related to heparan
sulfate, which binds to a range of target molecules and can
subsequently affect their activity [13]. Heparin is produced
endogenously by basophils andmast cells, and can be found in
a variety of organs. The GAG chains in heparin each contain
200–300 saccharide units, resulting in a variable molecular
weight. Heparin, isolated frommucosa of animals, is the most
widely used anticoagulant in the world [14]. It used to be the
drug of choice for the prevention and treatment of venous
thromboembolism (VTE), but since 1999 it has been replaced
by LMWHs [15]. LMWH variants such as dalteparin, nadro-
parin and tinzaparin are heparin fragments with less than 18
saccharide units per GAG chain and a molecular mass of
approximately 5000 Da. The anticoagulant activity of heparin
and LMWHs is indirect and largely based on binding of hep-
arin or heparin fragments to antithrombin 3 [16], a plasma
protease inhibitorwith the ability to inactivate several enzymes
of the coagulation cascade, including factors X and II. Heparin
also promotes tissue factor pathway inhibitor (TFPI) by neu-
tralizing the effects of tissue factor (TF), a high affinity
receptor for coagulation factor VII and therefore an important
initiator of the coagulation cascade [17]. Interestingly, TF has
been implicated in glioma biology and its expression seems to
be related to molecular subtype and to mutations in EGFR and
other genes implicated inGBM[18].Moreover, TFwas shown
to be the driver of growth activation of dormant GBM cells in
an in vivo model [19] and increased expression of TF is found
on microparticles in GBM patients [20].
Specific non-anticoagulant effects have been ascribed to
heparin as well. It downregulates the inflammatory
response by binding immune-activating enzymes and
inhibits adhesion of leukocytes to the endothelial wall [21].
Several animal studies and case reports also suggest a
beneficial effect on wound healing and tissue repair [22].
However, most research into non-anticoagulant effects of
heparin has focused on its impact in cancer [7, 23, 24].
GBM specific studies will be discussed below.
Preclinical data
Angiogenesis
One of the hallmarks of GBM is angiogenesis and
numerous factors have been shown to play an important
role in this process [25, 26]. Heparin and LMWH influence
angiogenesis by affecting some of these factors [27–31] as
discussed below.
Tumor-derived adhesion factor (TAF), also known as
mac25, is expressed in normal brain, lung, and muscle, but
also in various human cancer tissues [27]. In GBMs, TAF
is localized specifically in small blood vessels near tumor
cells. In vitro it co-localizes with collagen IV and is found
in tube-like structures of endothelial cells, indicating a role
in angiogenesis. TAF is a heparin binding protein and
heparin (10lg/ml) inhibits binding of TAF to endothelial
cells [27]. High concentrations of heparin (20lg/ml) pre-
vent the formation of tube-like structures by endothelial
cells, indicating the ability of heparin to inhibit early steps
of angiogenesis.
Secondly, heparin and tinzaparin (an LMWH) reduce
endothelial cell proliferation in a dose-dependent manner
in vitro [28]. Heparin was shown to bind to heparan sulfate
proteoglycans (HSPGs), preventing the ability of HSPGs to
act as co-receptors for pro-angiogenic factors and antago-
nizing proliferation in this way.
Hypoxia, an important feature of GBMs, has been shown
to influence several biological processes, including neovas-
cularization (mediated by vascular endothelial growth fac-
tor; VEGF) and activation of the coagulation system
(mediated by expression of TF) [32, 33]. Protease-activated
receptor 2 (PAR-2), a G-protein coupled receptor active in
coagulation dependent signaling, is up-regulated by hypoxia
and TF [34]. The induction of PARs was found to activate
heparin binding EGF-like growth factor (HB-EGF), a pro-
angiogenic growth factor [29]. Heparin can inhibit HB-EGF
activity through interference with HSPG binding, and also
reverse PAR-2 dependent proliferation of endothelial cells,
thereby inhibiting GBM neovascularization [29].
Moreover, in a U87-MG GBM xenograft mouse model
it has been shown that heparin can bind to hepatocyte
growth factor/scatter factor (HGF/SF), which plays a role
in tumorigenesis and angiogenesis and is expressed in
GBM [35]. Blocking of HGF/SF with heparin and a neu-
tralizing HGF antibody resulted in reduced tumor burden
due to decreased angiogenesis in vivo [30].
SU5416 is a tyrosine kinase receptor inhibitor that
inhibits both vascular endothelial growth factor receptor 2
(VEGFR-2) and c-kit [31]. Subsequently, this drug has
been shown to reduce vascular density in GBM [36].
In vivo, combined treatment with SU5416 and dalteparin
(an LMWH) enhanced the inhibition of tumor growth by
SU5416, whereas dalteparin alone did not result in reduced
tumor growth [31]. A possible explanation for this obser-
vation could be competitive binding of VEGF by LMWH
and SU5416. Combining LMWH with a VEGFR-2 inhi-
bitor (i.e. SU5416) could thereby promote the anti-angio-
genic effect of SU5416.
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Extracellular vesicles
Recently, accumulating evidence suggests that EVs,
50–1000 nm membrane vesicles released by all cell types,
play a role in tumor biology [8, 37]. For instance, EVs
derived from GBM cells have been shown to have a
stimulating effect on neovascularization, tumor cell growth
[8], and to modify monocytic cells [38]. EVs can be taken
up by recipient cells and transfer tumor-derived contents,
including functional RNAs, miRNAs and protein [9, 39].
Blocking the uptake of EVs has gained interest as a pos-
sible anti-cancer strategy. Recently, heparin has been
shown to block transfer of EVs into cells [10]. A heparin
concentration of 0.1 lg/ml resulted in a 90 % reduction in
EV uptake into U87-MG glioma cells in an in vitro co-
culture system. Other work showed that HSPGs on the
recipient cell surface act as a receptor for EVs, and that
these HSPGs can be inhibited in a dose dependent manner
by heparin or other HS mimetics [40]. These data suggest
that heparin interacts with tumor-derived EVs and blocks
attachment of EVs to recipient cells, which could possibly
result in an anti-tumor effect.
Extracellular matrix
Connecting to and modifying extracellular matrix (ECM)
proteins is crucial for survival and migration of (glioma)
cells [41]. Heparin has been shown to inhibit GBM cell-
attachment to laminin and fibronectin, two ECM proteins
[42]. A different study did not demonstrate enoxaparin (an
LMWH) to have a significant inhibitory effect on migration
of tumor cells in culture; tumor cell proliferation was
however inhibited [43]. This is not in line with what others
have observed, as Okumura and co-workers found an
increase of tumor cell proliferation by exposure of cells to
heparin [44]. Unfortunately, different cell culture condi-
tions, such as the presence of ECM or basic fibroblast
growth factor (bFGF), make it impossible to draw definite
conclusions.
Interaction with (potential) therapeutics
Targeted drug delivery for GBM treatment has gained
interest [45]. However, the delivery method has to meet
several requirements, such as bypassing the immune sys-
tem, crossing the blood–brain barrier, and selectively tar-
geting GBM cells. Low-density lipoprotein (LDL), an
endogenous carrier of cholesterol, could potentially meet
these requirements and was tested as a drug carrier tar-
geting GBM cells. LDL is of particular interest for drug
delivery, since LDL-receptor activity is increased in
dividing cells. LDL carrying the drug aclacinomycin A (I-
LDL-aclacinomycin A) was found to reduce tumor cell
growth in vitro [46]. The presence of heparin however,
inhibited receptor-mediated uptake of I-LDL-aclacino-
mycin A in a glioblastoma cell line [47], indicating that
heparin might inhibit receptor-mediated uptake and
degradation of LDL by tumor cells.
The same effect was observed when a viral vector was
used to deliver genes encoding anti-tumor proteins to GBM
cells. Using an AAV library to select capsid variants, a new
chimeric AAV vector was created that was able to suc-
cessfully transduce a multitude of glioma cell lines [48]. In
fact some serotypes of AAV (2, 3, 6 and 13) enter cells via
heparin binding [49]. Incubation of cells with the viral
vector in the presence of heparin can therefore greatly
reduce the transduction efficiency. Taking these results into
account, the combination of heparin and targeted drug
delivery such as LDL or an AAV vector could prove to be
counteractive.
Clinical data
Three studies describe the effect of heparin and/or LMWHs
on survival in human GBM patients [50–52].
In 2002, the Eastern Cooperative Oncology Group
(ECOG) initiated a controlled trial to investigate if LMWH
treatment, in combination with radiation therapy, could
improve overall survival (OS) in newly diagnosed GBM
patients [50]. The patient population for this trial consisted
of 42 supratentorial GBM patients with an estimated
expected survival of at least 8 weeks and an ECOG per-
formance status of 0–2. On the first day of radiotherapy,
LMWH (dalteparin) was introduced daily for a planned
24 months or until progression of disease, at a dose of
5000 IE subcutaneously which is considered a prophylactic
dose for VTE [15]. After first progression, patients could
continue dalteparin therapy in addition to standard regi-
mens. A comparable group of 72 patients was selected
from the Radiation Therapy Oncology Group (RTOG)
GBM database to serve as historical controls. Median
survival was 11.9 months in the trial group, a non-signifi-
cant improvement (P value of 0.47) compared to the RTOG
database cohort. Within the study group, a subgroup of four
patients who continued dalteparin after first (radiological)
progression had a median survival of 7.9 months, com-
pared to 3 months in the group who stopped LMWH
treatment. The study closed early as the original recruit-
ment goal seemed unrealistic after the introduction of
temozolomide as standard of care for GBM patients in
2004 [50].
The PRODIGE trial, a randomized placebo-controlled
trial, studied the effect of long term subcutaneous LMWH
(dalteparin) treatment in patients with newly diagnosed
high grade glioma (WHO grade 3 or 4) [51]. Primary
J Neurooncol (2015) 124:151–156 153
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endpoints were documented symptomatic deep venous
thrombosis (DVT) or pulmonary embolism occurring dur-
ing the 6 months post-randomization; secondary endpoints
were OS and hemorrhage. The treatment group received
5000 IE dalteparin subcutaneously daily, control glioma
patients were injected with saline. The trial faced diffi-
culties recruiting patients and was terminated early because
of insufficient study drug quantity and a trend towards
increased incidence of major bleeding in patients who
received LMWH. A total of 186 patients were randomized,
treated and analyzed. Long-term treatment with LMWH
did not result in improved survival rates, as the 12-month
mortality rates were 47.8 % for LMWH? and 45.4 % for
placebo patients, a non-significant difference. Twenty-two
patients developed VTE in the first six months: nine in the
LMWH? group and 13 in the placebo group [hazard ratio
(HR) = 0.51, 95 % confidence interval (CI): 0.19–1.4, P
value = 0.29]. At 12 months, there were five (5.1 %)
major bleeds in the LMWH? group and one (1.2 %) on
placebo (HR = 4.2, 95 % CI: 0.48–36, P value = 0.22).
A recent retrospective cohort study investigated the
effect of systemic LMWH in 30 GBM patients who
underwent surgical intervention (resection or biopsy) and
subsequent chemo-radiation and adjuvant temozolomide
therapy [52]. Thirteen patients received the LMWH
enoxaparin (4000 IU/day) for 6 weeks, and 17 did not. The
baseline characteristics age, gender, method of surgery and
performance status were similar in the two groups. Main
endpoints of the study were 1- and 2-year OS, an additional
endpoint was progression free survival.
One-year OS was 41.2 % in the LMWH- group and
84.6 % in the LMWH? patients (P value 0.016). Two-year
survival, median OS, and progression free survival were
also more favorable in the group that received LWMH,
although this difference was not significant. The addition of
LMWH did not increase temozolomide toxicity and no
DVT or bleeding occurred in either of the groups.
Discussion
Preclinical studies show an inhibitory effect of heparin and
LMWH on GBM growth and angiogenesis. As heparin and
LMWH are already widely used in cancer patients, they
seem attractive candidates for potential anti-GBM therapy.
Only three studies on the effect of heparin or LMWH in
GBM patients have been published [50–52]. The first study
showed increased survival in patients who continued dal-
teparin after first progression [50]. These results could have
been influenced by selection, as clinical status determined
treatment choice. The PRODIGE trial [51] was terminated
early, before significant results could be observed. Zincir-
cioglu et al. showed in a small trial, which included, contrary
to the first two studies, patients who received temozolomide
in combination with radiotherapy, that 2-year OS was
improved by daily injections of LMWH [52]. However, the
study groups were not randomly chosen, as the group treated
with LMWH had risk factors for VTE, which was the reason
and indication for anticoagulant therapy. The non-treatment
group lacked such risk factors, making the groups less
comparable at baseline. On the other hand it could be stated
that the LMWH? group showed improved OS in spite of
their increased risk factors for VTE; a hopeful indication that
additional trials should be undertaken.
Studies have attempted to define precise risks (bleeding,
thrombocytopenia) and benefits of different heparin vari-
ants in overall cancer treatment. A 2013 Cochrane review
renders an overview [6]. Nine described trials included
patients with a variety of cancer types and stages, mostly
solid tumors. The overall effect of parenteral administered
heparin/LMWH therapy on the survival of cancer patients
was significant at 24 months, but not at 12 months. At
24 months, the mortality risk ratio for the heparin/LMWH
treated group was 0.92 (95 % CI 0.88–0.97). Other meta-
analyses show similar results, with a non-significant trend
towards a beneficial effect of LMWH on cancer patient
survival [7, 53–56].
A potential drawback of the use of heparin as a drug
targeting GBM angiogenesis, migration, and growth are the
anticoagulant properties of heparin/LMWH. For this rea-
son, most cancer patients will receive heparin/LMWH for a
limited period of time. Potentially, these short exposure
times could influence the anti-cancer effect, resulting in no
concrete survival benefits.
To avoid the anticoagulant effects, and thereby risk of
major bleeding, heparin mimetic agents have been devel-
oped that lack anticoagulant effects [28, 57–60]. These
mimics could possibly be administered in higher concen-
trations and longer treatment regimes. In several tumor
models promising results have been shown. In a human
gastric carcinoma mouse model, N-desulfated heparin
(lacking anticoagulant effects) was shown to decrease
metastasis, tumor angiogenesis and levels of bFGF [57]. A
comparison of LMWH enoxaparin and non-anticoagulant
LMWH (NA-LMWH) treatment of a B16F10 melanoma
mouse model indicated that both drugs reduced lung tumor
formation, while only enoxaparin prolonged blood clotting
time [58]. Another heparin-like compound, M402, inhib-
ited tumor cell migration and sprouting in vitro and
demonstrated a survival benefit in a murine mammary
carcinoma model [60]. In a mouse model of pancreatic
cancer, sulfated non-anticoagulant heparins (S-NACH) as
well as the LMWH tinzaparin inhibited tumor growth and
angiogenesis [59]. Prolonged bleeding time and hemor-
rhage were absent in the S-NACH treated group, in contrast
to the tinzaparin treated mice. In contrast, another study on
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a heparan sulfate antibody (aHS), intended to target
HSPGs like heparin does, found that aHS stimulated
angiogenesis in primary human ECs [28]. This effect was
counteracted by heparin. Beneficial anti-tumor effects of
non-anticoagulant heparins in GBM models have not yet
been published yet.
Although the preliminary results as described in this
review may be promising, a well-designed trial is yet to be
conducted. Choice of the study drug is debatable: a com-
monly used LMWH seems self-evident, as this is the
common VTE prophylaxis and LMWHs are already widely
prescribed. However, with the possible increased risk of
(intracranial) hemorrhage, a non-anticoagulant heparin or
heparin mimetics should be taken into consideration.
Without the increased bleeding risk, greater liberty exists
regarding dosage and a significant therapeutic effect could
potentially be achieved.
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